SeLux Diagnostics, Inc.
SeLux’s Next Generation Phenotyping (NGP) platform provides rapid, high-throughput, fully-automated AST results, enabling same-shift susceptibility testing of up to 50 antibiotics in parallel. The platform is driven by SeLux’s proprietary assay, which differentiates antibiotic-induced bacterial growth modes with a surface-binding fluorescent amplifier.
Address Charlestown, MA 02129
Microbiology Product Areas
ClinicalNOTE: The products listed in this section may not be approved for clinical diagnostic use in your jurisdiction. You must assume these products are unregulated and therefore cannot be used for routine testing and reporting of results unless otherwise stated.
|Antibiotic Resistance||Show all suppliers|
|Antibiotic Sensitivity||Show all suppliers|
|Antimicrobial Resistance (AMR)||Show all suppliers|